UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback